Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Fan, P; Liu, L; Yin, Y; Zhao, Z; Zhang, Y; Amponsah, PS; Xiao, X; Bauer, N; Abukiwan, A; Nwaeburu, CC; Gladkich, J; Gao, C; Schemmer, P; Gross, W; Herr, I.
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Cancer Lett. 2016; 373(1):130-137
Web of Science PubMed FullText FullText_MUG


Authors Med Uni Graz:
Schemmer Peter

Dimensions Citations:

Plum Analytics:
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal malignancies and resistance to chemotherapy prevents the therapeutic outcome. MicroRNAs provide a novel therapeutic strategy. Here, the established and primary human PDA cell lines PANC-1, AsPC-1, MIA-PaCa2, AsanPaCa, BxPC-3 and three gemcitabine-resistant subclones were examined. A gene expression profiling revealed that the ribonucleotide reductase M1 (RRM1) was upregulated in gemcitabine-resistant cells, which was confirmed by qRT-PCR, Western blot analysis and immunostaining. Inhibition of RRM1 by lipotransfection of siRNA reduced its expression and reversed gemcitabine resistance. The expression of RRM1 correlated to gemcitabine resistance in vitro and was higher in malignant patient pancreas tissue compared to non-malignant pancreas tissue. By microRNA expression profiling, we identified microRNA-101-3p as top-downregulated candidate. Lipotransfection of microRNA-101-3p mimics inhibited the expression of RRM1, reduced the luciferase activity of its 3'UTR and sensitized for gemcitabine-induced cytotoxicity. These results underline the relevance of microRNA-101-3p-driven regulation of RRM1 in drug resistance and suggest the co-delivery of microRNA-101-3p and gemcitabine for more effective therapy outcome. Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
3' Untranslated Regions -
Antimetabolites, Antineoplastic - pharmacology
Binding Sites -
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - enzymology
Carcinoma, Pancreatic Ductal - genetics
Carcinoma, Pancreatic Ductal - pathology
Cell Line, Tumor -
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
Dose-Response Relationship, Drug -
Drug Resistance, Neoplasm - genetics
Gene Expression Profiling - methods
Gene Expression Regulation, Enzymologic -
Gene Expression Regulation, Neoplastic -
Humans -
MicroRNAs - genetics
MicroRNAs - metabolism
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - enzymology
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - pathology
RNA Interference -
Time Factors -
Transfection -
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Up-Regulation -

Find related publications in this database (Keywords)
© Meduni GrazImprint